EPRX
Eupraxia Pharmaceuticals Inc.
$6.52
+0.18 (+2.84%)
At close · Jul 15
Market Cap
$425.93M
Shares
65,326,947
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.52
Open$6.34
Day$6.19–6.56
52W$4.88–9.32
Avg vol 30d350K
Short int5.5M · 8.4% float · 9.0d
Short vol24%
DataApr 2024–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.7 · calm
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−7%
below
Price vs 50-day avg
−3%
below
RSI (14)
49
neutral
MACD trend
Positive
52-week position
37%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+7%
trailing
6-month return
−28%
trailing
YTD return
−14%
this year
Relative strength
−38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+54% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.36% of float · ▲ +18.8% MoM · 9.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
54 holders — near 2-yr high, broad support
Squeeze score
76
high risk · 0–100
Fundamentals
EPS growth
−36%
Y/Y
Balance sheet
$80.6M
net cash
Quant / Vol
risk profile
Volatility
60%
annualized · 1-yr
Max drawdown
−35%
past year
ATR
6.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−7%
Bearish
Price vs 50-day avg
−3%
Neutral
RSI (14)
49
Neutral
MACD trend
Positive
Bullish
52-week position
37%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+54% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.36% of float · ▲ +18.8% MoM · 9.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
54 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $5
Now $7 · 37%
52-wk high $9
vs 200-day avg -7%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EPRX
this stock
Eupraxia Pharmaceuticals Inc.
|
$425.93M | -13.6% | — | — | 8.4% |
|
ONC
BeOne Medicines Ltd.
|
$449.85B | +2.5% | +22179.2% | 915.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +5.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -13.8% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EPRX | -5.8% | +6.7% | -27.8% | -1.4% | -13.6% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -7.0% | +6.9% | -37.9% | -2.4% | -24.3% |